ORA, Inc.
Quick facts
Marketed products
- Lastacaft ® · Ophthalmology / Allergy
Lastacaft is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in the eye. - Olopatadine Nasal Spray · Allergy / Immunology
Olopatadine is a selective H1-receptor antagonist and mast cell stabilizer that blocks histamine-mediated allergic responses in the nasal mucosa. - Patanol · Other
- Prednisolone Acetate 0.12% · Ophthalmology
Prednisolone acetate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. - Rohto (r) Hydra · Ophthalmology
Rohto Hydra is an ophthalmic lubricant that provides moisture and relief to dry eyes by forming a protective hydrating layer on the ocular surface. - Saline Nasal Spray · Otolaryngology / Respiratory
Saline nasal spray delivers a sterile salt-water solution to the nasal passages to cleanse, moisturize, and relieve nasal congestion. - Systane (r) Ultra · Ophthalmology
Systane Ultra is a lubricating eye drop that provides sustained moisture and relief to the ocular surface by forming a protective film. - Tears Naturale II Ophthalmic Solution · Ophthalmology
Tears Naturale II is an artificial tear solution that lubricates and protects the ocular surface by mimicking natural tear composition.
Phase 3 pipeline
- PL9643 Ophthalmic Solution · Ophthalmology
PL9643 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production in ocular tissues. - Placebo Ophthalmic Solution · Ophthalmology
This is a placebo ophthalmic solution, meaning it has no active therapeutic effect. - ST-100 (vezocolmitide) · Oncology
ST-100 (vezocolmitide) is a small molecule that modulates the Wnt/β-catenin signaling pathway.
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: